SlideShare ist ein Scribd-Unternehmen logo
1 von 30
Anticancer Drug Screening ‘ Cancer’: a fatal disease of uncontrolled proliferation of genetically altered cells. In all known cases, cancer cells are derived from the repeated divisions of a mutant cell. Some of these mutations may be due to the effects of carcinogens, such as tobacco smoke, radiation, chemicals or infectious agents. A few other cancer-promoting mutations may be acquired through errors in DNA replication.  Genetic alterations that render a normal cell cancerous usually arise in two classes of genes termed the oncogenes and tumors suppressors.  Activate the cancer promoting oncogenes and/or inactivate the tumor suppressor genes.  Cancer
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Need for Novel Anticancer Agents ,[object Object],[object Object],[object Object],[object Object]
In vitro cytotoxicity studies ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
[object Object],[object Object],[object Object],[object Object]
Figure-1: Normal (Control) HeLa cells  showing no signs of necrosis or apoptosis Figure-2: Effect of Doxorubicin on HeLa cells showing cell shrinkage, nuclear condensation  Figure-3: Effect of compound - 6 on HeLa cells showing apoptosis and cell necrosis Figure-4: Effect of Com -4 on HeLa cells showing cell shrinkage and nuclear condensation
Cell Cycle Analysis Control R6 R3 R4 R5 DOX R6 R3 R4 R5 Phase Sub-G 0 G 0 -G1 S G 2 -M Phase Sub-G 0 G 0 -G 1 S G 2 -M % cells 1.15 74.27 6.34 18.65 % cells 2.22 16.62 4.01 76.76 Figure-7: Control HeLa cells  showing normal cell cycle  Figure-8: Doxorubicin showing prominent G 2 -M phase arrest
BE-7 R5 R2 R3 R4 BE-4 R6 R3 R4 R5 Phase Sub-G 0 G 0 -G 1 S G 2 -M Phase Sub-G 0 G 0 -G 1 S G 2- M % cells 27.87 44.46 9.73 17.91 % cells 0.62 88.41 1.04 9.72 Figure-9: Com-6 treated  HeLa cells  showing sub G 0  (apoptotic) arrest Figure-10: Com-4 treated HeLa cells showing prominent  G 0 -G 1   phase arrest
 
In Vivo Study Goals: Animal Models ,[object Object],[object Object],[object Object],[object Object],[object Object]
Animal Models Proof of Principle ,[object Object],[object Object],[object Object],[object Object]
Ideal Animal Model ,[object Object],[object Object],[object Object],[object Object],“ There is no perfect tumor model”
Animal Models in Cancer ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
IN VIVO  ANTICANCER ACTIVITY   ,[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],Group No. Treatment Dose Route 1 Control-S (2% gum acacia) Equivolume i.p 2 Cisplatin 3.5 mg/kg i.p 3 Control-A (2% gum acacia) Equivolume i.p 4 Compound-A 50 mg/kg i.p 5 Control-B Equivolume i.p 6 Compound-B 50 mg/kg i.p 7 Control-C Equivolume i.p 8 Compound-C 50 mg/kg i.p
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Solid tumor model using DLA cell lines ,[object Object],[object Object],[object Object],[object Object],[object Object]
Parameters Monitored ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Human Tumor Xenografts ,[object Object],[object Object],[object Object],[object Object],[object Object]
Murine Xenograft Sites ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Xenograft Study Endpoints ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Xenograft Tumor Weight Change ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Xenograft Advantages ,[object Object],[object Object],[object Object],[object Object]
Xenograft Disadvantages ,[object Object],[object Object],[object Object],[object Object],[object Object]
Other Animal Models ,[object Object],[object Object],[object Object],[object Object],[object Object]
In Vivo Hollow Fiber Assay ,[object Object],[object Object],[object Object],[object Object],[object Object]
Thank you

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Invitro Screening of Anti-Cancer Drugs.
Invitro Screening of Anti-Cancer Drugs.Invitro Screening of Anti-Cancer Drugs.
Invitro Screening of Anti-Cancer Drugs.
 
Assignment on Preclinical and clinical screening of anti cancer drugs
Assignment on Preclinical and clinical screening of anti cancer drugsAssignment on Preclinical and clinical screening of anti cancer drugs
Assignment on Preclinical and clinical screening of anti cancer drugs
 
In vitro methods of screening of anticancer agents
In vitro methods of screening of anticancer agentsIn vitro methods of screening of anticancer agents
In vitro methods of screening of anticancer agents
 
Screening of hepatoprotective drugs
Screening of hepatoprotective drugsScreening of hepatoprotective drugs
Screening of hepatoprotective drugs
 
Screening of anticancer drugs
Screening of anticancer drugsScreening of anticancer drugs
Screening of anticancer drugs
 
Assignment on Limitation of animal experimentation
Assignment on Limitation of animal experimentationAssignment on Limitation of animal experimentation
Assignment on Limitation of animal experimentation
 
Screening models for immunomodulator
Screening models for immunomodulatorScreening models for immunomodulator
Screening models for immunomodulator
 
Anti- Tumor assay / Screening of Anticancer Drugs
Anti- Tumor assay / Screening of Anticancer DrugsAnti- Tumor assay / Screening of Anticancer Drugs
Anti- Tumor assay / Screening of Anticancer Drugs
 
Immunoassay of digoxin
Immunoassay of digoxinImmunoassay of digoxin
Immunoassay of digoxin
 
Screening antianginal (1)
Screening antianginal (1)Screening antianginal (1)
Screening antianginal (1)
 
Screening methods of Cancer
Screening methods of CancerScreening methods of Cancer
Screening methods of Cancer
 
Preclinical screening of anti fertility agents
Preclinical screening of anti fertility agentsPreclinical screening of anti fertility agents
Preclinical screening of anti fertility agents
 
screening of antiulcer agents
screening  of antiulcer agentsscreening  of antiulcer agents
screening of antiulcer agents
 
Preclinical screening of antiallergics
Preclinical screening of antiallergicsPreclinical screening of antiallergics
Preclinical screening of antiallergics
 
Invivo screening methods for anti inflammatory agents
Invivo screening methods for anti inflammatory  agentsInvivo screening methods for anti inflammatory  agents
Invivo screening methods for anti inflammatory agents
 
Preclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic DrugsPreclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic Drugs
 
Screening models on aphrodisiac agents
Screening models on aphrodisiac agentsScreening models on aphrodisiac agents
Screening models on aphrodisiac agents
 
Pre clinical screening of anti fertility drugs
Pre clinical screening of anti fertility drugsPre clinical screening of anti fertility drugs
Pre clinical screening of anti fertility drugs
 
Immunoassay of insulin (neha)
Immunoassay of insulin (neha)Immunoassay of insulin (neha)
Immunoassay of insulin (neha)
 
Screening method of nootropics vikas malik
Screening method of nootropics vikas malikScreening method of nootropics vikas malik
Screening method of nootropics vikas malik
 

Ähnlich wie Anticancer drug screening

Anticancer activity studies
Anticancer activity studiesAnticancer activity studies
Anticancer activity studies
shishirkawde
 
Metastatic Breast Cancer
Metastatic Breast CancerMetastatic Breast Cancer
Metastatic Breast Cancer
Chen Yan
 
Principles of cell viability assays by surendra.pptx
Principles of cell viability assays by surendra.pptxPrinciples of cell viability assays by surendra.pptx
Principles of cell viability assays by surendra.pptx
Surendra Chowdary
 
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
Jing Zang
 

Ähnlich wie Anticancer drug screening (20)

Anticancer activity studies
Anticancer activity studiesAnticancer activity studies
Anticancer activity studies
 
Antioxidant and Antitumor Activities on Catunaregum spinosa
Antioxidant and Antitumor Activities on Catunaregum spinosaAntioxidant and Antitumor Activities on Catunaregum spinosa
Antioxidant and Antitumor Activities on Catunaregum spinosa
 
Pre clinical screening models for anti cancer drugs
Pre clinical screening models for anti cancer drugsPre clinical screening models for anti cancer drugs
Pre clinical screening models for anti cancer drugs
 
Suppress lung cancer progression via up regulation of linc rna-p21
Suppress lung cancer progression via up regulation of linc rna-p21Suppress lung cancer progression via up regulation of linc rna-p21
Suppress lung cancer progression via up regulation of linc rna-p21
 
Animal models in developmental therapeitocs
Animal models in developmental therapeitocsAnimal models in developmental therapeitocs
Animal models in developmental therapeitocs
 
Metastatic Breast Cancer
Metastatic Breast CancerMetastatic Breast Cancer
Metastatic Breast Cancer
 
M0557376
M0557376M0557376
M0557376
 
scd%2E2014%2E0405
scd%2E2014%2E0405scd%2E2014%2E0405
scd%2E2014%2E0405
 
Inhibition of hdac by vorinostat in human lung cancer cells
Inhibition of hdac by vorinostat in human lung cancer cellsInhibition of hdac by vorinostat in human lung cancer cells
Inhibition of hdac by vorinostat in human lung cancer cells
 
Screening
ScreeningScreening
Screening
 
MTTlab flyer A4
MTTlab flyer A4MTTlab flyer A4
MTTlab flyer A4
 
Cancer treatment
Cancer treatment Cancer treatment
Cancer treatment
 
Principles of cell viability assays by surendra.pptx
Principles of cell viability assays by surendra.pptxPrinciples of cell viability assays by surendra.pptx
Principles of cell viability assays by surendra.pptx
 
Chemotherapy of cancer
Chemotherapy of cancerChemotherapy of cancer
Chemotherapy of cancer
 
AntineoplasticAgentsby KEMISA. HASSEN ZAINABU
AntineoplasticAgentsby KEMISA. HASSEN ZAINABU AntineoplasticAgentsby KEMISA. HASSEN ZAINABU
AntineoplasticAgentsby KEMISA. HASSEN ZAINABU
 
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
 
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
IMMUNOHISTOCHEMICAL ALTERATIONS IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED ...
 
Ijsrp p10758
Ijsrp p10758Ijsrp p10758
Ijsrp p10758
 
inducing Apoptosis in cancer cell by natural compounds and screening methods
inducing Apoptosis in cancer cell by natural compounds and screening methodsinducing Apoptosis in cancer cell by natural compounds and screening methods
inducing Apoptosis in cancer cell by natural compounds and screening methods
 
Mouse models of colorectal cancer
Mouse models of colorectal cancerMouse models of colorectal cancer
Mouse models of colorectal cancer
 

Mehr von shishirkawde

Mehr von shishirkawde (11)

Qsar
QsarQsar
Qsar
 
Presentation apc
Presentation apcPresentation apc
Presentation apc
 
Monte carlo
Monte carloMonte carlo
Monte carlo
 
Ion exchange chromatography
Ion exchange chromatographyIon exchange chromatography
Ion exchange chromatography
 
Intermolecular interactions
Intermolecular interactionsIntermolecular interactions
Intermolecular interactions
 
Hplc final
Hplc finalHplc final
Hplc final
 
Flash chromatography
Flash chromatographyFlash chromatography
Flash chromatography
 
Biotransformation
BiotransformationBiotransformation
Biotransformation
 
Biotin
BiotinBiotin
Biotin
 
A seminar on design of ligands for known
A seminar on design of ligands for knownA seminar on design of ligands for known
A seminar on design of ligands for known
 
Qsar lecture
Qsar lectureQsar lecture
Qsar lecture
 

Kürzlich hochgeladen

Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Safe Software
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Safe Software
 

Kürzlich hochgeladen (20)

Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
 
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
 
MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024
 
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
DEV meet-up UiPath Document Understanding May 7 2024 AmsterdamDEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
 
Exploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone ProcessorsExploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone Processors
 
How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
 
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ..."I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
 
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
 
Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...
 
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemkeProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
ProductAnonymous-April2024-WinProductDiscovery-MelissaKlemke
 
[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
 
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
 
Ransomware_Q4_2023. The report. [EN].pdf
Ransomware_Q4_2023. The report. [EN].pdfRansomware_Q4_2023. The report. [EN].pdf
Ransomware_Q4_2023. The report. [EN].pdf
 
Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdfBoost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdf
 
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectorsMS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectors
 

Anticancer drug screening

  • 1. Anticancer Drug Screening ‘ Cancer’: a fatal disease of uncontrolled proliferation of genetically altered cells. In all known cases, cancer cells are derived from the repeated divisions of a mutant cell. Some of these mutations may be due to the effects of carcinogens, such as tobacco smoke, radiation, chemicals or infectious agents. A few other cancer-promoting mutations may be acquired through errors in DNA replication. Genetic alterations that render a normal cell cancerous usually arise in two classes of genes termed the oncogenes and tumors suppressors. Activate the cancer promoting oncogenes and/or inactivate the tumor suppressor genes. Cancer
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. Figure-1: Normal (Control) HeLa cells showing no signs of necrosis or apoptosis Figure-2: Effect of Doxorubicin on HeLa cells showing cell shrinkage, nuclear condensation Figure-3: Effect of compound - 6 on HeLa cells showing apoptosis and cell necrosis Figure-4: Effect of Com -4 on HeLa cells showing cell shrinkage and nuclear condensation
  • 8. Cell Cycle Analysis Control R6 R3 R4 R5 DOX R6 R3 R4 R5 Phase Sub-G 0 G 0 -G1 S G 2 -M Phase Sub-G 0 G 0 -G 1 S G 2 -M % cells 1.15 74.27 6.34 18.65 % cells 2.22 16.62 4.01 76.76 Figure-7: Control HeLa cells showing normal cell cycle Figure-8: Doxorubicin showing prominent G 2 -M phase arrest
  • 9. BE-7 R5 R2 R3 R4 BE-4 R6 R3 R4 R5 Phase Sub-G 0 G 0 -G 1 S G 2 -M Phase Sub-G 0 G 0 -G 1 S G 2- M % cells 27.87 44.46 9.73 17.91 % cells 0.62 88.41 1.04 9.72 Figure-9: Com-6 treated HeLa cells showing sub G 0 (apoptotic) arrest Figure-10: Com-4 treated HeLa cells showing prominent G 0 -G 1 phase arrest
  • 10.  
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.

Hinweis der Redaktion

  1. 12/01/11
  2. 12/01/11
  3. 12/01/11
  4. 12/01/11
  5. 12/01/11
  6. 12/01/11
  7. 12/01/11
  8. 12/01/11
  9. 12/01/11
  10. 12/01/11
  11. 12/01/11
  12. 12/01/11
  13. 12/01/11
  14. 12/01/11
  15. 12/01/11
  16. 12/01/11
  17. 12/01/11
  18. 12/01/11
  19. 12/01/11
  20. 12/01/11
  21. 12/01/11
  22. 12/01/11
  23. 12/01/11
  24. 12/01/11
  25. 12/01/11
  26. 12/01/11
  27. 12/01/11
  28. 12/01/11
  29. 12/01/11